H.C. Wainwright lowered the firm’s price target on UroGen Pharma (URGN) to $55 from $64 and keeps a Buy rating on the shares. The company reported a “modest” revenue miss, but its long-term outlook is “still promising,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN: